[Treatment of metastatic renal adenocarcinomas with combined recombinant alpha-2a interferon and vinblastine].
The results of treatment of metastatic renal cell carcinoma have so far been very poor. Many phase II studies have shown that interferon alpha therapy is active in a significant proportion of patients (approximately 10 to 15% complete and partial remission). In the hope of improving these results we have conducted a phase I-II study of the combination of interferon alpha-2a and vinblastine in 21 patients with metastatic renal cell cancer. Side-effects were pronounced and the mean tolerated doses were 12.5 x 10(6) U/m2 interferon alpha three times per week and 0.10 mg/kg vinblastine once every three weeks. We observed a 43% response rate, with 1 complete remission, 8 partial remissions, 4 stabilizations and 8 progressions. These very encouraging results need to be confirmed by large scale studies.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000628:therapy; D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors; D014747:Vinblastine / Q000627:therapeutic use*
D007370:Interferon Type I; D011994:Recombinant Proteins; D014747:Vinblastine
Traitement des adénocarcinomes rénaux métastatiques par l'association interféron recombinant alpha-2a et vinblastine.